RxDoctor Payments Data

Yan Kiriakov, DO

Family Medicine · Furlong, PANPI 1467863324

Payments from drug & device makers

$2,555in general payments, 2019–2025

Across 99 payments — averaging $25.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$345
  • AstraZeneca$301
  • Qiagen, LLC$258
  • Johnson & Johnson$249
  • Astellas Pharma US Inc$211
  • Bausch Health US, LLC$193
  • plus $998 from 18 others

What the payments were for

  • Food & beverage$2,40994%
  • Education$1466%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,555 in reported general payments places this provider in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$86,287
Medicare patients
148
Services billed
1,129

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide62$68,275
EliquisApixaban52$46,546
RybelsusSemaglutide29$34,884
JardianceEmpagliflozin23$33,409
FarxigaDapagliflozin Propanediol24$24,390
WegovySemaglutide18$21,795
GemtesaVibegron15$14,047
OzempicSemaglutide16$13,986
LinzessLinaclotide19$10,935
InvokanaCanagliflozin11$7,333
VascepaIcosapent Ethyl15$5,324
MovantikNaloxegol Oxalate13$5,312
Testosterone16$4,617
Icosapent Ethyl14$3,703
Rosuvastatin Calcium100$1,763

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Wegovy, Ozempic$345$70,66563 claims
Lilly USA, LLCMounjaro$98$68,27562 claims
PfizerEliquis$138$46,54652 claims
AstraZenecaFarxiga$301$24,39024 claims
Sumitomo Pharma America, Inc.Gemtesa$71$14,04715 claims
Johnson & JohnsonInvokana$249$7,33311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Furlong

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →